Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis

Frontiers in Medicine

Medicine

Xingling Zeng¹  Wenting Hu²  Tianying Tan²  Shuangshuang Li²  Tinghui Yue²  Xiaochao Chen³  Xiangdong Zhao⁴  Tianbao Xiao⁵  Qi Zeng⁶ 

[1] Clinical Medicine College, Chengdu University of Traditional Chinese Medicine, Chengdu, China;College of Clinical Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China;Colorectal and Anal Surgery, Chengdu Anorectal Hospital, Chengdu, Sichuan, China;Colorectal and Anal Surgery, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China;Colorectal and Anal Surgery, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China;School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China;

关键词: non-small cell lung cancer;    nab-paclitaxel;    chemotherapy;    efficacy;    safety;    meta-analysis;   

DOI  :  10.3389/fmed.2023.1139248

 received in 2023-01-06, accepted in 2023-06-19,  发布年份 2023

来源: Frontiers

【 摘 要 】

PurposeThis meta-analysis was exerted in assessing the anticancer efficacy and safety of nab-paclitaxel (nab-P) when combined with platinum compound agents for therapy in patients with non-small cell lung cancer (NSCLC).MethodWe systematically searched the following seven electronic databases: PubMed, Cochrane Library, Web of Science, Embase, CNKI, Wan Fang, and China Science and Technology Journal Data. Randomized comparative clinical [randomized controlled clinical trial (RCT)] studies on nab-P plus platinum and carboplatin or cisplatin in combination with conventional chemotherapy agents or traditional paclitaxel were searched.ResultsA total of 19 RCT studies involving 6,011 patients were analyzed. The primary outcome includes the overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). The secondary outcome includes adverse events (AEs). Nab-P combined with platinum (carboplatin/cisplatin) had a better ORR [odds ratio (OR) = 1.66, 95% confidence interval (CI) (1.34, 2.05), p < 0.001] and improved PFS [hazard ratio (HR) = 0.84, 95% CI: (0.74, 0.94), p = 0.01] and OS [HR = 0.86, 95% CI: (0.78, 0.96), p = 0.008] in NSCLC patients. ORR [OR = 2.18, 95% CI: (1.07, 4.43)], PFS [HR = 0.62, 95% CI: (0.40, 0.97)], and OS [HR = 0.63, 95% CI: (0.49, 0.81)] were significantly improved among patients aged >70 years, and ORR [OR = 1.80, 95% CI: (1.20, 2.70)] and PFS [HR = 0.74, 95% CI: (0.56, 0.97)] were significantly elevated with SCC rate ≥65% in NSCLC patients (all p > 0.05). Among the adverse effects, the prevalence of neutropenia, neuralgia, and arthralgia/myalgia (≥ grade 3) compared to that of the control group. On the other hand, the prevalence of anemia and thrombocytopenia was higher in the nab-P plus platinum (carboplatin/cisplatin) compared to that of controls. It is worth noting that fatigue did not show statistical significance.ConclusionNab-P in combination with carboplatin/cisplatin regimen improves efficacy and tolerability in patients with NSCLC.Systematic review registrationhttp://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022288499.

【 授权许可】

Unknown   
Copyright © 2023 Tan, Li, Hu, Yue, Zeng, Zeng, Chen, Zhao and Xiao.